Before any medication is started, patients go through a full metabolic workup, relevant lab testing, and a real planning conversation about goals, expectations, and potential obstacles
Inhibition of Intestinal SGLT1 with Mizagliflozin for the Treatment of Post-bariatric Hypoglycemia J Endocr Soc
Applying the previously mentioned mechanism of DIT to tirzepatide, it is plausible that antibodies could form against tirzepatide-platelet complexes, promoting platelet destruction through Fc receptor-mediated phagocytosis or complement activation and cell lysis
Usually, these symptoms start to fade within a few days or weeks as your body gets used to the medicine
For patients switching, there is a need for seeking professional guidance before making changes to their treatment plan, especially when transitioning between medications with different mechanisms and dosing schedules